Home | XHANCE® (fluticasone propionate)

XHANCE Targets Delivery Where Chronic Sinusitis Occurs^1-3

XHANCE uses the Exhalation Delivery System^TM to reach the site of inflammation³

XHANCE is the
FIRST and ONLY

FDA-approved treatment for adults with chronic rhinosinusitis without nasal polyps

Administration

Standard-delivery nasal steroids deliver predominately to the anterior nasal cavity with minimal deposition above and behind the turbinates, ostiomeatal complex, and superior nasal regions.⁴

Goes to the Exhalation Delivery System pageLearn More

Graphic of XHANCE SAVINGS CARD. Receive Your Initial Prescription For as Little as $0*. *See back of card for terms and conditions

Affordability and Access

Eligible, commercially insured patients can pay as little as $0 for their prescription of XHANCE.*

Goes to the Xhance Xtended Patient Support pageLearn More

*These offers are not valid for use by cash-paying patients or patients enrolled in Medicare, Medicaid, and TRICARE or other federal or state programs. Offers are subject to quantity limitations. Maximum benefits per fill apply. Patient cost share may impact benefits and eligibility. Optinose^® reserves the right to rescind, revoke, or amend this offer without notice. Click here for additional terms and conditions.

References:

Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2024.
Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res. 2013;3(1):42-62.
Leopold DA, Elkayam D, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol. 2019;143(1):126-134.e5.
Leach CL, Kuehl PJ, Chand R, McDonald JD. Nasal deposition of HFA-beclomethasone, aqueous fluticasone propionate and aqueous mometasone furoate in allergic rhinitis patients. J Aerosol Med Pulm Drug Deliv. 2015;28(5):334-340.

INDICATIONS

XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:

Chronic rhinosinusitis without nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis.
Chronic rhinosinusitis with nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.

References:

Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2024.
Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res. 2013;3(1):42-62.
Leopold DA, Elkayam D, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol. 2019;143(1):126-134.e5.
Leach CL, Kuehl PJ, Chand R, McDonald JD. Nasal deposition of HFA-beclomethasone, aqueous fluticasone propionate and aqueous mometasone furoate in allergic rhinitis patients. J Aerosol Med Pulm Drug Deliv. 2015;28(5):334-340.

XHANCE is the FIRST and ONLY

FDA-approved treatment for adults with chronic rhinosinusitis without nasal polyps

XHANCE is the
FIRST and ONLY